Abstract:The Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic transcription factors, which participate in cellular responses to cytokines and growth factors. STAT3 is found constitutively activated in many types of cancer. Its activation occurs when the Tyrosine residue 705 (Tyr 705) is phosphorylated, monomers form dimmers, and dimmers translocate to the nucleus. Dimerized STAT3 binds to specific DNA response elements and leads to increase the transcription of its downstream genes including angiogenesis, anti-apoptosis, cell cycle progression and proliferation. Therefore, STAT3 is a potential target for cancer therapy. Evidence shows that inhibiting STAT3 using dominant-negative STAT3, antisense oligonucleotides and RNA interference induces tumor cell death. Interleukin 6 (IL-6) is a multifunctional cytokine and its family also comprises cardiotrophine-1 (CT-1), ciliary neurotrophic factor (CNTF), IL-11, leukaemia inhibitory factor (LIF) and oncostatin M (OSM). IL-6 signals through its receptor sIL-6-6R, gp130, Janus kinases (JAKs). A growing numbers of evidence demonstrate that tumorigenesis caused by STAT3 is mediated by IL-6 signals. Therefore, targeting IL-6/STAT3 signaling should be considered for the treatment of patients with higher levels of IL-6/STAT3 signaling. We previously reported that a novel small molecule, LLL12, inhibits STAT3 phosphorylation on Tyr 705 in human cancer cells leading to apoptosis in vitro and suppressed tumor growth in vivo. In this study, we showed that LLL12 also inhibited IL-6 induced STAT3 phosphorylation in human liver and pancreactic cancer cell lines. PANC-1 (pancreatic cancer cell) and Hep3B (liver cancer cell line) were treated with different doses of IL-6 for 30 minutes. Immunofluorecent results showed that IL-6 induced STAT3 phosphorylation on Tyr 705 in these two cancer cell lines. Western blot analysis further indicated that the induction of its phosphorylation was IL-6 dose dependent. To determine whether LLL-12 would inhibit IL-6 induced STAT3 phosphorylation, we pre-treated cells with LLL12 for 2 hours followed by IL-6 treatment for 30 minutes and found that STAT3 phosphorylation was suppressed in cells pre-treated with LLL12. LLL12 pre-treatment also blocked STAT3 translocation to the nucleus. To address whether LLL12 pre-treatment would affect STAT1 phosphorylation, we induced STAT1 with IFN-γ and found that LLL12 did not influence STAT1 phosphorylation. To assess the effects of LLL12 on other factors through IL-6/STAT3 pathway, we analyzed JAKs and observed that IL-6 had no effects on JAK1 phosphorylation, but it induced JAK2 phosphorylation. LLL12 pre-treatment did not suppress JAK2 phosphorylation. In conclusion, structure-based small molecule LLL12 selectively inhibited STAT3 phosphorylation induced by IL-6 and may be a potent agent to target IL-6/STAT3 signaling in cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2275.

Tyrosine kinase inhibitor A77-1726 inhibiting STAT6 phosphorylation and c-fos expression induced by IL-13

Upregulation of Proto-Oncogene C-Mpl by Interleukin-13 in Dami Cells

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

[Tyrosine Kinases Inhibitor A77 1726 Inhibits Upregulation of Collagen Generation in Fibroblasts Induced by IL-13].

Il-13 Upregulates Gpiib Expression in Megakaryocytic Cell Lines Via Stat6

Effects of IL-13 on Fibroblast Proliferation and Transcription Factor c-fos Expression

The Effect of Recombinant Human Interleukin-13 on Expression of Proto-Oncogene C-Mpl of Dami Cells

Up-regulation of collagen synthesis and STAT6 phosphorylation by interleukin-13 in fibroblasts

Abstract 2275: A novel small molecule, LLL12, inhibits IL-6 induced STAT3 phosphorylation and nuclear translocation

IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation

IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway

2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition Via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells

Effects of IL-13 on SDF-1 and EGF expression in fibroblasts co-cultured with breast cancer cells

Effect Of Il-13r Alpha 2 On Tgf-Beta Expression And Collagen Synthesizing Induced By Il-13 In Human Lung Fibroblasts Hfl-1

Inhibitory Effect of Soluble IL-13 Receptor Alpha 2 on Fibroblast Collagen Synthesis

Abstract 5542: Characterization of a long-acting IL-13 super-antagonist engineered to target tumor associated macrophages and myeloid cells

Effect of IL-13 Rα 2 on TGF-β expression and collagen synthesizing induced by IL-13 in human lung fibroblasts HFL-1

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway

Inhibition of Interleukin-13 Gene Expression by Triptolide in Activated T Lymphocytes

IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats

P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis